Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370(1):85–90.
   PubMed Web of Science ®Google Scholar
• Weiss EM, Wunderlich R, Ebel N, et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol. 2012;2:132.
   PubMedGoogle Scholar
• Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol. 2010;22(3):132–143.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines. 2015;3(2):344–372.
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A, Mine T, et al. Recent advances in cancer vaccines: an overview. Japan J Clin Oncol. 2008;39(2):73–80.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Acquavella N, Yu Z, et al. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011;239(1):27–44.
   PubMed Web of Science ®Google Scholar
• Shumway NM, Ibrahim N, Ponniah S, et al. Therapeutic breast cancer vaccines: a new strategy for early-stage disease. BioDrugs. 2009;23(5):277–287.
   PubMed Web of Science ®Google Scholar
• Liu SY, Wei W, Yue H, et al. Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy. Biomaterials. 2013;34(33):8291–8300.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Investig. 2018;128(11):5184.
   PubMed Web of Science ®Google Scholar
• Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med. 2012;18(9):1332–1334.
   PubMed Web of Science ®Google Scholar
• Nahas MR, Rosenblatt J, Lazarus HM, et al. Anti-cancer vaccine therapy for hematologic malignancies: an evolving era. Blood Rev. 2018;32(4):312–325.
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72(10):2473–2480.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–322.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692.
   PubMed Web of Science ®Google Scholar
• Zi F, He J, He D, et al. Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11(5):3203–3211.
   PubMed Web of Science ®Google Scholar
• Pleshkan VV, Alekseenko IV, Tyulkina DV, et al. Fibroblast activation protein (FAP) as a possible target of an antitumor strategy. Mol Genet Microbiol Virol. 2016;31(3):125–134.
   Web of Science ®Google Scholar
• Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 2009;4(11):e7965.
   PubMed Web of Science ®Google Scholar
• Loeffler M, Kruger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Investig. 2006;116(7):1955–1962.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010;101(11):2325–2332.
   PubMed Web of Science ®Google Scholar
• Chen M, Xiang R, Wen Y, et al. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci Rep. 2015;5(1):14421.
   PubMed Web of Science ®Google Scholar
• Fredriksen AB, Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood. 2007;110(6):1797–1805.
   PubMed Web of Science ®Google Scholar
• Huebener N, Fest S, Hilt K, et al. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Mol Cancer Ther. 2009;8(8):2392–2401.
   PubMed Web of Science ®Google Scholar
• Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000;6(10):1160–1166.
   PubMed Web of Science ®Google Scholar
• He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003;278(24):21831–21836.
   PubMed Web of Science ®Google Scholar
• Strioga MM, Darinskas A, Pasukoniene V, et al. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? Vaccine. 2014;32(32):4015–4024.
   PubMed Web of Science ®Google Scholar
• Barnas JL, Simpson-Abelson MR, Yokota SJ, et al. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 2010;3(1):29–47.
   PubMedGoogle Scholar
• Cavallo F, Forni G. Recent advances in cancer immunotherapy with an emphasis on vaccines. Expert Rev Vac. 2009;8(1):25–28.
   PubMedGoogle Scholar
• Bi Y, Wei L, Mao HT, et al. Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors. Zhonghua Zhong Liu Za Zhi [Chin J Oncol]. 2008;30(10):749–753.
   PubMedGoogle Scholar
• Quandt D, Seliger B. “Tumor immunology meets oncology” (TIMO) X, May 23–24, 2014, Halle/Saale, Germany. Cancer Immunol Immunother. 2015;64(4):519–526.
   PubMed Web of Science ®Google Scholar
• Vertuani S, Triulzi C, Roos AK, et al. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother. 2009;58(5):653–664.
   PubMed Web of Science ®Google Scholar
• Grzelak A, Polakova I, Smahelova J, et al. Experimental combined immunotherapy of tumours with major histocompatibility complex class I downregulation. Int J Mol Sci. 2018;19(11):3693.
   PubMed Web of Science ®Google Scholar
• Janakiram M, Abadi YM, Sparano JA, et al. T cell coinhibition and immunotherapy in human breast cancer. Discov Med. 2012;14(77):229–236.
   PubMed Web of Science ®Google Scholar
• Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm. 2011;8(3):635–641.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268–276.
   PubMed Web of Science ®Google Scholar
• Guo G, Cui Y. New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J Immunother Cancer. 2015;3(1):9.
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Aranda F, et al. Trial watch-small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016;5:e1149674.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Kommineni N, Khan W. Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol Res. 2017;126:109–122.
   PubMed Web of Science ®Google Scholar
• Comes A, Rosso O, Orengo AM, et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol. 2006;176(3):1750–1758.
   PubMed Web of Science ®Google Scholar
• Disis ML. Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment. Clin Cancer Res. 2009;15(21):6476–6478.
   PubMed Web of Science ®Google Scholar
• Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205–215.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20:pii: E840.
   Web of Science ®Google Scholar
• Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother. 2006;55(4):433–442.
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhang FF, Geng F, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein alpha by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother. 2016;65(5):613–624.
   PubMed Web of Science ®Google Scholar
• Yi T, Wei YQ, Tian L, et al. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther. 2007;14(2):158–164.
   PubMed Web of Science ®Google Scholar
• Genoud N, Ott D, Braun N, et al. Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am J Pathol. 2008;172(5):1287–1296.
   PubMed Web of Science ®Google Scholar
• Zhang G, Li J, Li S, et al. Exploring spatial trends and influencing factors for gastric cancer based on Bayesian statistics: a case study of Shanxi, China. Int J Environ Res Public Health. 2018;15.
   Web of Science ®Google Scholar
• Turcotte S, Gros A, Hogan K, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 2013;191(5):2217–2225.
   PubMed Web of Science ®Google Scholar